Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial

Autor: Jia-Min Ma, Qing-Han Gao, Yi-Qiong Guo, Meng-Wei Zhang, Jian-Qiang Yu, Lu-Lu Gao, Lin Li, Xiu-Juan Tao, Yanna Fan, Yu-Xiang Li, Jian-Jun Yang
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Trials
Trials, Vol 22, Iss 1, Pp 1-9 (2021)
ISSN: 1745-6215
Popis: Background Non-alcohol fatty liver disease (NAFLD) is the most common chronic liver disease in the world, with a high incidence and no effective treatment. At present, the targeted therapy of intestinal microbes for NAFLD is highly valued. Lycium barbarum polysaccharide (LBP), as the main active ingredient of Lycium barbarum, is considered to be a new type of prebiotic substance, which can improve NAFLD by regulating the gut microbiota. The purpose of this study is to evaluate the safety and efficacy of LBP supplementation in modulating gut microbiota for NAFLD patients. Methods This randomized, double-blind, placebo-control study will be conducted in the physical examination center of the Ningxia Hui Autonomous Region People’s Hospital. A total of 50 patients with NAFLD confirmed by abdominal ultrasound, laboratory tests, and questionnaire surveys will be recruited and randomly assigned into the control group (maltodextrin placebo capsules) and the intervention group (LBP supplementation capsules) for 3 months. Neither patients, nor investigators, nor data collectors will know the contents in each capsule and the randomization list. The primary outcome measure is the level of ALT concentration relief after the intervention. Secondary outcomes include gut microbiota abundance and diversity, intestinal permeability, patient’s characteristic demographic data and body composition, adverse effects, and compliance from patients. Discussion LBPs are potential prebiotics with the property of regulating host gut microbiota. Our previous studies have documented that LBP supplement can improve the liver damage and the gut microflora dysbiosis in NAFLD rats. This treatment would provide a more in-depth understanding of the effect of this LBP supplementation. Trial registration Chinese Clinical Trial Register, ChiCTR2000034740. Registered on 17 July 2020.
Databáze: OpenAIRE
Externí odkaz: